REFERENCES
- Jabs D A, Rosenbaum J T, Foster C S, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000; 130: 492–513, [PUBMED], [INFOTRIEVE], [CSA]
- Van O E, Zins B J, Sandborn W J, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut. 1996; 39: 63–68, [CSA]
- Bergan S, Rugstad H E, Bentdal O, et al. Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. Ther Drug Monit. 1994; 16: 13–20, [PUBMED], [INFOTRIEVE], [CSA]
- Chan G L, Erdmann G R, Gruber S A, et al. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol. 1990; 30: 358–363, [PUBMED], [INFOTRIEVE], [CSA]
- Stolk J N, Boerbooms A M, De Abreu R A, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1998; 41: 1858–1866, [PUBMED], [INFOTRIEVE], [CSA]
- Singh G, Fries J F, Spitz P, Williams C A. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum. 1989; 32: 837–843, [PUBMED], [INFOTRIEVE], [CSA]
- Singh G, Fries J F, Williams C A, et al. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 1991; 18: 188–194, [PUBMED], [INFOTRIEVE], [CSA]
- Szumlanski C L, Honchel R, Scott M C, Weinshilboum R M. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics. 1992; 2: 148–159, [PUBMED], [INFOTRIEVE], [CSA]
- Leipold G, Schotz E, Haas J P, Oellerich M. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum. 1997; 40: 1896–1898, [PUBMED], [INFOTRIEVE], [CSA]
- Gaffney K, Scott D G. Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Br J Rheumatol. 1998; 37: 824–836, [PUBMED], [INFOTRIEVE], [CSA]
- Andrasch R H, Pirofsky B, Burns R P. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol. 1978; 96: 247–251, [PUBMED], [INFOTRIEVE], [CSA]
- Dees C, Arnold J J, Forrester J V, Dick A D. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol. 1998; 116: 1456–1461, [PUBMED], [INFOTRIEVE], [CSA]
- Yazici H, Pazarli H, Barnes C G, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990; 322: 281–285, [PUBMED], [INFOTRIEVE], [CSA]
- Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome. Arthritis Rheum. 1997; 40: 769–774, [PUBMED], [INFOTRIEVE], [CSA]
- Kötter I, Dürk H, Saal J, et al. Therapy of Behçet's disease. Ger J Ophthalmol. 1996; 5: 92–97, [CSA]
- BenEzra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol. 1986; 70: 589–592, [PUBMED], [INFOTRIEVE], [CSA]
- Hooper P L, Kaplan H J. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 1991; 98: 944–952, [PUBMED], [INFOTRIEVE], [CSA]
- Michel S S, Ekong A, Baltatzis S, Foster C S. Multifocal choroiditis and panuveitis. Ophthalmology. 2002; 109: 378–383, [PUBMED], [INFOTRIEVE], [CSA]
- Purvin V, Ranson N, Kawasaki A. Idiopathic recurrent neuroretinitis: effects of long-term immunosuppression. Arch Ophthalmol. 2003; 121: 65–67, [PUBMED], [INFOTRIEVE], [CSA]
- Foster C S, Wilson L A, Ekins M B. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology. 1982; 89: 340–353, [PUBMED], [INFOTRIEVE], [CSA]
- Mondino B J, Brown S I. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol. 1983; 96: 453–459, [PUBMED], [INFOTRIEVE], [CSA]
- Neumann R, Tauber J, Foster C S. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology. 1991; 98: 858–862, [PUBMED], [INFOTRIEVE], [CSA]
- Tauber J, Sainz de la Maza M, Foster C S. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea. 1991; 10: 185–195, [PUBMED], [INFOTRIEVE], [CSA]
- Miserocchi E, Baltatzis S, Roque M R, et al. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology. 2002; 109: 111–118, [PUBMED], [INFOTRIEVE], [CSA]
- Herman R A, Veng-Pedersen P, Hoffman J, et al. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci. 1989; 78: 165–171, [PUBMED], [INFOTRIEVE], [CSA]
- Kozloski G D, De Vito J M, Kisicki J C, et al. The effect of food on the absorption of methotrexate sodium tablets in healthy volunteers. Arthritis Rheum. 1992; 35: 761–764, [PUBMED], [INFOTRIEVE], [CSA]
- Dupuis L L, Koren G, Shore A, et al. Methotrexate-nonsteroidal anti-inflammatory drug interaction in children with arthritis. J Rheumatol. 1990; 17: 1469–1473, [PUBMED], [INFOTRIEVE], [CSA]
- Thomas M H, Gutterman L A. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol. 1986; 13: 440–441, [PUBMED], [INFOTRIEVE], [CSA]
- Kremer J M, Alarcon G S, Lightfoot R W, jr, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum. 1994; 37: 316–328, [PUBMED], [INFOTRIEVE], [CSA]
- Walker A M, Funch D, Dreyer N A, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 1993; 36: 329–335, [PUBMED], [INFOTRIEVE], [CSA]
- Weinblatt M E. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol. 1985; 12: 35–39, [CSA]
- Weinblatt M E, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum. 1989; 32: 1592–1596, [PUBMED], [INFOTRIEVE], [CSA]
- Kamel O W, van de Rijn M, Weiss L M, et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993; 328: 1317–1321, [PUBMED], [INFOTRIEVE], [CSA]
- Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm. 2001; 9: 35–40, [PUBMED], [INFOTRIEVE], [CSA]
- Holz F G, Krastel H, Breitbart A, et al. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol. 1992; 1: 142–144, [PUBMED], [INFOTRIEVE], [CSA]
- Shah S S, Lowder C Y, Schmitt M A, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992; 99: 1419–1423, [PUBMED], [INFOTRIEVE], [CSA]
- Kaplan-Messas A, Barkana Y, Avni I, Neumann R. Methotrexate as a first-line corticosteroid sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003; 11: 131–139, [PUBMED], [INFOTRIEVE], [CSA]
- Samson C M, Waheed N, Baltatzis S, Foster C S. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001; 108: 1134–1139, [PUBMED], [INFOTRIEVE], [CSA]
- Weiss A H, Wallace C A, Sherry D D. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr. 1998; 133: 266–268, [PUBMED], [INFOTRIEVE], [CSA]
- Dev S, McCallum R M, Jaffe G J. Methotrexate treatment for sarcoidosis-associated panuveitis. Ophthalmology. 1999; 106: 111–118, [PUBMED], [INFOTRIEVE], [CSA]
- Gion N, Stavrou P, Foster C S. Immunomodulatory therapy for chronic tubulointerstitial nephritis-associated uveitis. Am J Ophthalmol. 2000; 129: 764–768, [PUBMED], [INFOTRIEVE], [CSA]
- Bullingham R E, Nicholls A J, Kamm B R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998; 34: 429–455, [PUBMED], [INFOTRIEVE], [CSA]
- Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol. 1996; 41: 513–516, [PUBMED], [INFOTRIEVE], [CSA]
- Schiff M H, Leishman B. Long-term safety of CellCept (mycophenolate mofetil), a new therapy for rheumatoid arthritis. Arthritis Rheum. 1998; 41(Suppl)S155, [CSA]
- European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet. 1995; 345: 1321–1325, [CSA]
- The Tricontinental Mycophenolate Mofetile Renal Transplantation Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996; 61: 1029–1037, [CSA]
- Kilmartin D J, Forrester J V, Dick A D. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet. 1998; 352: 35–36, [PUBMED], [INFOTRIEVE], [CSA]
- Larkin G, Lightman S. Mycophenolate mofetil: a useful immunosuppressive in inflammatory eye disease. Ophthalmology. 1999; 106: 370–374, [PUBMED], [INFOTRIEVE], [CSA]
- Zierhut M, Stübiger N, Aboalchamat W, . Immunosuppressive therapy with mycophenolate mofetil (CellCept) in the treatment of uveitis. Uveitis in the Third Millenium., E M Dodds, C A Couto, et al. Elsevier Science, Amsterdam 2000; 127–131
- Baltatzis S, Tufail F, Yu E N, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disease. Ophthalmology. 2003; 110: 1061–1065, [PUBMED], [INFOTRIEVE], [CSA]
- Sen H N, Suhler E B, Al-Khatib S Q, et al. Mycophenolate mofetil for the treatment of scleritis. Ophthalmology. 2003; 110: 1750–1755, [PUBMED], [INFOTRIEVE], [CSA]
- Makinodan T, Santos G W, Quinn R P. Immunosuppressive drugs. Pharmacol Rev. 1970; 22: 189–247, [PUBMED], [INFOTRIEVE], [CSA]
- Fauci A S, Wolff S M, Johnson J S. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med. 1971; 285: 1493–1496, [PUBMED], [INFOTRIEVE], [CSA]
- Fleming R A. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997; 17: 146S–154S, [PUBMED], [INFOTRIEVE], [CSA]
- Bagley C MJ, Bostick F W, DeVita V T, JR. Clinical pharmacology of cyclophosphamide. Cancer Res. 1973; 33: 226–233, [PUBMED], [INFOTRIEVE], [CSA]
- Pryor B D, Bologna S G, Kahl L E. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 1996; 39: 1475–1482, [PUBMED], [INFOTRIEVE], [CSA]
- Fauci A S, Haynes B F, Katz P, Wolff S M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983; 98: 76–85, [PUBMED], [INFOTRIEVE], [CSA]
- Guillevin L, Cordier J F, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997; 40: 2187–2198, [PUBMED], [INFOTRIEVE], [CSA]
- Goren M P. Oral mesna: a review. Semin Oncol. 1992; 19: 65–71, [PUBMED], [INFOTRIEVE], [CSA]
- Talar-Williams C, Hijazi Y M, Walther M M, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996; 124: 477–484, [PUBMED], [INFOTRIEVE], [CSA]
- Rosenbaum J T. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol. 1994; 21: 123–125, [PUBMED], [INFOTRIEVE], [CSA]
- Özyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol. 1992; 76: 241–243, [CSA]
- Kazokoglu H, Saatçi O, Cuhadaroglu H, Eldem B. Long-term effects of cyclophosphamide and colchicine treatment in Behcet's disease. Ann Ophthalmol. 1991; 23: 148–151, [PUBMED], [INFOTRIEVE], [CSA]
- Ando K, Fujino Y, Hijikata K, et al. Epidemiological features and visual prognosis of Behçet's disease. Jpn J Ophthalmol. 1999; 43: 312–317, [PUBMED], [INFOTRIEVE], [CSA]
- Akpek E K, Jabs D A, Tessler H H, et al. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology. 2002; 109: 1506–1513, [PUBMED], [INFOTRIEVE], [CSA]
- Jabs D A, Mudun A, Dunn J P, Marsh M J. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000; 130: 469–476, [PUBMED], [INFOTRIEVE], [CSA]
- Charles S J, Meyer P AR, Watson P G. Diagnosis and management of systemic Wegener's granulomatosis presenting with anterior ocular inflammatory disease. Br J Ophthalmol. 1991; 75: 201–207, [PUBMED], [INFOTRIEVE], [CSA]
- Hoang-Xuan T, Foster C S, Rice B A. Scleritis in relapsing polychondritis: response to therapy. Ophthalmology. 1990; 97: 892–898, [CSA]
- Elder M J, Lightman S, Dart J KG. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol. 1995; 79: 264–266, [PUBMED], [INFOTRIEVE], [CSA]
- Newell D R, Calvert A H, Harrap K R, McElwain T J. Studies on the pharmacokinetics of chlorambucil and prednimustine in man. Br J Clin Pharmacol. 1983; 15: 253–258, [PUBMED], [INFOTRIEVE], [CSA]
- Cannon G W, Jackson C G, Samuelson C OJ, et al. Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review. Semin Arthritis Rheum. 1985; 15: 106–118, [PUBMED], [INFOTRIEVE], [CSA]
- Miserocchi E, Baltatzis S, Ekong A, et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology. 2002; 109: 137–142, [PUBMED], [INFOTRIEVE], [CSA]
- Goldstein D A, Fontanilla F A, Kaul S, et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002; 109: 370–377, [PUBMED], [INFOTRIEVE], [CSA]
- Tabbara K F. Chlorambucil in Behçet's disease: a reappraisal. Ophthalmology. 1983; 90: 906–908, [PUBMED], [INFOTRIEVE], [CSA]
- O'Duffy J D, Robertson D M, Goldstein N P. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med. 1984; 76: 75–84, [PUBMED], [INFOTRIEVE], [CSA]
- Elliott J H, Ballinger W H. Behçet's syndrome: treatment with chlorambucil. Trans Am Ophthalmol Soc. 1984; 82: 264–281, [PUBMED], [INFOTRIEVE], [CSA]
- Pivetti Pezzi P, Gasparri V, De Liso P, Catarinelli G. Prognosis in Behcet's disease. Ann Ophthalmol. 1985; 17: 20–25, [PUBMED], [INFOTRIEVE], [CSA]
- BenEzra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol. 1986; 70: 589–592, [PUBMED], [INFOTRIEVE], [CSA]
- Tessler H H, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease. Br J Ophthalmol. 1990; 74: 353–357, [PUBMED], [INFOTRIEVE], [CSA]
- Mudun A B, Ergen A, Ipcioglu S U, et al. Short-term chlorambucil for refractory uveitis in Behçet's disease. Ocul Immunol Inflamm. 2001; 9: 219–229, [PUBMED], [INFOTRIEVE], [CSA]
- Jennings T, Tessler H H. Twenty cases of sympathetic ophthalmia. Br J Ophthalmol. 1989; 73: 140–145, [PUBMED], [INFOTRIEVE], [CSA]
- Palmer R G, Kanski J J, Ansell B M. Chlorambucil in the treatment of intractable uveitis associated with juvenile chronic arthritis. J Rheumatol. 1985; 12: 967–970, [PUBMED], [INFOTRIEVE], [CSA]
- Kauppi M J, Savolainen H A, Anttila V-J, Isomäki H A. Increased risk of leukaemia in patients with juvenile chronic arthritis treated with chlorambucil. Acta Pediatr. 1996; 85: 248–250, [CSA]
- Pollak R, Wong R L, Chang C T. Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group. Ther Drug Monit. 1999; 21: 661–663, [PUBMED], [INFOTRIEVE], [CSA]
- Choc M G. Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral vs. Sandimmune. Int J Dermatol. 1997; 36(Suppl 1)1–6, [PUBMED], [INFOTRIEVE], [CSA]
- Friman S, Backman L. A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features. Clin Pharmacokinet. 1996; 3: 181–193, [CSA]
- Kahan B D. Drug therapy: cyclosporine. N Engl J Med. 1989; 25: 1725–1737, [CSA]
- Stein C M, Pincus T, Yocum D, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks; an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum. 1997; 40: 1843–1851, [PUBMED], [INFOTRIEVE], [CSA]
- Landewe R B, Goei T H, van Rijthoven A W, et al. Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis. J Rheumatol. 1994; 21: 1631–1636, [PUBMED], [INFOTRIEVE], [CSA]
- Rodriguez F, Krayenbuhl J C, Harrison W B, et al. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry. Arthritis Rheum. 1996; 39: 1491–1498, [PUBMED], [INFOTRIEVE], [CSA]
- Deray G, Benhmida M, Le Hoang P, et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med. 1992; 117: 578–583, [PUBMED], [INFOTRIEVE], [CSA]
- Van d enBorne B E, Landewe R B, Houkes I, et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum. 1998; 41: 1930–1937, [CSA]
- Nussenblatt R B, Palestine A G, Rook A H, et al. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. 1983; ii: 235–238, [CSA]
- Nussenblatt R B, Palestine A G, Chan C-C. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983; 96: 275–282, [PUBMED], [INFOTRIEVE], [CSA]
- Nussenblatt R B, Palestine A G, Chan C-C. Cyclosporine therapy for uveitis: long-term follow-up. J Ocul Pharmacol. 1985; 1: 369–382, [PUBMED], [INFOTRIEVE], [CSA]
- Graham E M, Sanders M D, James D G, et al. Cyclosporin A in the treatment of posterior uveitis. Trans Ophthalmol Soc UK. 1985; 104: 146–151, [PUBMED], [INFOTRIEVE], [CSA]
- BenEzra D, Cohen E, Rakotomalala M, et al. Treatment of endogenous uveitis with cyclosporine A. Transplant Proc. 1988; 20: 122–127, [PUBMED], [INFOTRIEVE], [CSA]
- Wakefield D, McCluskey P. Cyclosporine: a therapy in inflammatory eye disease. J Ocul Pharmacol. 1991; 7: 221–226, [PUBMED], [INFOTRIEVE], [CSA]
- Towler H MA, Cliffe A M, Whiting P H, Forrester J V. Low dose cyclosporin A therapy in chronic posterior uveitis. Eye. 1989; 3: 282–287, [PUBMED], [INFOTRIEVE], [CSA]
- Towler H MA, Whiting P H, Forrester J V. Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation. Eye. 1990; 4: 514–520, [PUBMED], [INFOTRIEVE], [CSA]
- Secchi A G, De Rosa C, Pivetti-Pezzi P, et al. Open noncontrolled multicenter long-term trial with ciclosporin in endogenous non-infectious uveitis. Ophthalmologica. 1991; 202: 217–224, [PUBMED], [INFOTRIEVE], [CSA]
- Pascalis L, Pia G, Aresu G, et al. Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis. J Autoimmun. 1993; 6: 467–480, [PUBMED], [INFOTRIEVE], [CSA]
- Leznoff A, Shea M, Binkley K E, et al. Cyclosporine in the treatment of nonmicrobial inflammatory ophthalmic disease. Can J Ophthalmol. 1992; 6: 302–306, [CSA]
- Vitale A T, Rodriguez A, Foster C S. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 1996; 103: 365–374, [PUBMED], [INFOTRIEVE], [CSA]
- Palestine A G, Nussenblatt R B, Gelato M. Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine. Transplant Proc. 1988; 20: 131–135, [PUBMED], [INFOTRIEVE], [CSA]
- Blank M, Palestine A, Nussenblatt R, Shoenfeld Y. Down-regulation of autoantibody levels of cyclosporine and bromocriptine treatment in patients with uveitis. Clin Immunol Immunopathol. 1990; 54: 87–97, [PUBMED], [INFOTRIEVE], [CSA]
- Walton R C, Nussenblatt R B, Whitcup S M. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology. 1998; 105: 2028–2034, [PUBMED], [INFOTRIEVE], [CSA]
- Kilmartin D J, Forrester J V, Dick A D. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol. 1998; 82: 737–742, [PUBMED], [INFOTRIEVE], [CSA]
- de Smet M D, Rubin B I, Whitcup S M, et al. Combined use of cyclosporine and ketoconazole in the treatment of endogenous uveitis. Am J Ophthalmol. 1992; 113: 687–690, [PUBMED], [INFOTRIEVE], [CSA]
- Ramadan A M, Nussenblatt R B, de Smet M D. Long-term follow-up of patients with chronic uveitis affecting the posterior pole treated with combination cyclosporine and ketoconazole. Ophthalmology. 1997; 104: 706–711, [PUBMED], [INFOTRIEVE], [CSA]
- de Vries J, Baarsma G S, Zaal M JW, et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol. 1990; 74: 344–349, [PUBMED], [INFOTRIEVE], [CSA]
- Nussenblatt R B, Palestine A G, Chan C C, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991; 112: 138–146, [PUBMED], [INFOTRIEVE], [CSA]
- Nussenblatt R B, de Smet M D, Rubin B, et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. Am J Ophthalmol. 1993; 115: 583–591, [PUBMED], [INFOTRIEVE], [CSA]
- Müftüoglu AÜ, Pazarli H, Yurdakul S, et al. Short term cyclosporin A treatment of Behçet's disease. Br J Ophthalmol. 1987; 71: 387–390, [CSA]
- Caspers-Velu L E, Decaux G, Libert J. Cyclosporin in Behçet's disease resistant to conventional therapy. Ann Ophthalmol. 1989; 21: 111–118, [PUBMED], [INFOTRIEVE], [CSA]
- Diaz-Llopis M, Cervera M, Menezo J L. Cyclosporin A treatment of Behçet's disease: a long-term study. Curr Eye Res. 1990; 9(Suppl)17–23, [PUBMED], [INFOTRIEVE], [CSA]
- Chavis P S, Antonios S R, Tabbara K F. Cyclosporine effects on optic nerve and retinal vasculitis in Behçet's disease. Doc Ophthalmol. 1992; 80: 133–142, [PUBMED], [INFOTRIEVE], [CSA]
- Sajjadi H, Soheilian M, Ahmadieh H, et al. Low dose cyclosporin-A therapy in Behcet's disease. J Ocul Pharmacol. 1994; 10: 553–560, [PUBMED], [INFOTRIEVE], [CSA]
- Whitcup S M, Salvo E C, Nussenblatt R B. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease. Am J Ophthalmol. 1994; 118: 39–45, [PUBMED], [INFOTRIEVE], [CSA]
- Atmaca L S, Batioglu F. The efficacy of cyclosporin-A in the treatment of Behçet's disease. Ophthalmic Surg. 1994; 25: 321–327, [PUBMED], [INFOTRIEVE], [CSA]
- Hayasaka S, Kawamoto K, Noda S, Kodama T. Visual prognosis in patients with Behçet's disease receiving colchicines, systemic corticosteroid or cyclosporin. Ophthalmologica. 1994; 208: 210–213, [PUBMED], [INFOTRIEVE], [CSA]
- Süllü Y, Öge I, Erkan D, et al. Cyclosporin. A therapy in severe uveitis of Behçet's disease. Acta Ophthalmol Scand. 1998; 76: 96–99, [CSA]
- Özdal P C, Ortaç S, Taskintuna I, Firat E. Long-term therapy with low dose cyclosporin A in ocular Behçet's disease. Doc Ophthalmol. 2002; 105: 301–312, [CSA]
- BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc. 1988; 20: 136–143, [PUBMED], [INFOTRIEVE], [CSA]
- Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicines and long-term open study of cyclosporin in Behçet's disease. Lancet. 1989; 1: 1093–1096, [PUBMED], [INFOTRIEVE], [CSA]
- Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology. 1999; 106: 586–589, [PUBMED], [INFOTRIEVE], [CSA]
- Kato Y, Numaga J, Kato S, et al. Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A. Clin Exp Ophthalmol. 2001; 29: 335–336, [CSA]
- Le Hoang P, Girard B, Deray G, et al. Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc. 1988; 20: 128–130, [PUBMED], [INFOTRIEVE], [CSA]
- Vitale A T, Rodriguez A, Foster C S. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology. 1994; 101: 822–831, [PUBMED], [INFOTRIEVE], [CSA]
- Secchi A G, Tognon M S, Maselli C. Cyclosporin-A in the treatment of serpiginous choroiditis. Int Ophthalmol. 1990; 14: 295–399, [CSA]
- Chan C-C, Roberge F G, Whitcup S M, Nussenblatt R B. 32 cases of sympathetic ophthalmia: a retrospective study at the National Eye Institute, Bethesda, MD, from 1982 to 1992. Arch Ophthalmol. 1995; 113: 597–600, [PUBMED], [INFOTRIEVE], [CSA]
- Wakefield D, McCluskey P. Cyclosporin therapy for severe scleritis. Br J Ophthalmol. 1989; 73: 743–746, [PUBMED], [INFOTRIEVE], [CSA]
- Hakin K N, Ham J, Lightman S L. Use of cyclosporin in the management of steroid dependent non-necrotising scleritis. Br J Ophthalmol. 1991; 75: 340–341, [PUBMED], [INFOTRIEVE], [CSA]
- McCarthy J M, Dubord P J, Chalmers A, et al. Cyclosporine A for the treatment of necrotizing scleritis and corneal melting in patients with rheumatoid arthritis. J Rheumatol. 1992; 19: 1358–1361, [PUBMED], [INFOTRIEVE], [CSA]
- Woon W H, Stanford M R, Graham E M. Severe idiopathic posterior scleritis in children. Eye. 1995; 9: 570–574, [PUBMED], [INFOTRIEVE], [CSA]
- Spencer C M, Goa K L, Gillis J C. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs. 1997; 54: 925–975, [PUBMED], [INFOTRIEVE], [CSA]
- Japanese FK 506 Study Group on Refractory Uveitis. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Transplant Proc. 1991; 6: 3343–3346, [CSA]
- Mochizuki M, Ikeda E, Shirao M, et al. Preclinical and clinical study of FK506 in uveitis. Curr Eye Res. 1992; 11(Suppl)87–95, [PUBMED], [INFOTRIEVE], [CSA]
- Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 1993; 115: 763–769, [PUBMED], [INFOTRIEVE], [CSA]
- Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol. 1994; 118: 723–729, [PUBMED], [INFOTRIEVE], [CSA]
- Kilmartin D J, Forrester J V, Dick A D. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm. 1998; 6: 101–109, [PUBMED], [INFOTRIEVE], [CSA]
- Sloper C ML, Powell R J, Dua H S. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999; 106: 723–728, [PUBMED], [INFOTRIEVE], [CSA]
- Letko E, Ahmed A R, Foster C S. Treatment of ocular cicatricial pemphigoid with tacrolimus (FK 506). Graefe's Arch Clin Exp Ophthalmol. 2001; 239: 441–444, [CSA]
- Kalvakolanu D V, Borden E C. An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest. 1996; 14: 25–53, [PUBMED], [INFOTRIEVE], [CSA]
- Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today. 1996; 17: 369–372, [PUBMED], [INFOTRIEVE], [CSA]
- Physicians Desk Reference. Medical Economics Company, Montvale, NJ 2000; 2654–2658; 2808–2817
- Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997; 26: 1134–1215, [CSA]
- Guyer D R, Tiedeman J, Yannuzzi L A, et al. Interferon-associated retinopathy. Arch Ophthalmol. 1993; 111: 350–356, [PUBMED], [INFOTRIEVE], [CSA]
- Conlon K C, Urba W J, Smith J W, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 1990; 65: 2237–2242, [PUBMED], [INFOTRIEVE], [CSA]
- Kötter I, Eckstein A K, Stübiger N, Zierhut M. Treatment of ocular symptoms of Behçet's disease with interferon α 2a: a pilot study. Br J Ophthalmol. 1998; 82: 488–494, [CSA]
- Wechsler B, Bodaghi B, Huong D LT, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm. 2000; 8: 293–301, [PUBMED], [INFOTRIEVE], [CSA]
- Hamuryudan V, Özyazgan Y, Fresko Y, et al. Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study. Isr Med Assoc J. 2002; 4: 928–930, [PUBMED], [INFOTRIEVE], [CSA]